Identification of the E1fE1k cholinesterase genotype

Area of Science:

• Pharmacogenetics
• Biochemistry
• Human Genetics

Background:

• Cholinesterase enzymes play a critical role in drug metabolism, particularly for neuromuscular blocking agents like suxamethonium.
• Genetic variations in cholinesterase genes can lead to altered enzyme activity and adverse drug reactions.
• Prolonged apnea after suxamethonium is a known, albeit rare, complication linked to specific cholinesterase genotypes.

Purpose of the Study:

• To investigate the genetic basis of prolonged apnea following suxamethonium administration in a patient.
• To identify the specific cholinesterase alleles and genotype segregating within the affected family.
• To characterize the genetic factors contributing to atypical pseudocholinesterase activity.

Main Methods:

• Family-based genetic analysis was performed to identify segregation of cholinesterase alleles.
• Phenotypic characterization of enzyme activity was assessed.
• Genotyping was conducted to determine the specific alleles (A, F, K) and resulting genotype.

Main Results:

• The proband experienced prolonged apnea after suxamethonium, indicating atypical cholinesterase activity.
• The family was found to be segregating for the A, F, and K alleles at cholinesterase locus 1.
• The oldest son was identified with the E1fE1k genotype, explaining the observed pharmacogenetic variation.

Conclusions:

• The E1fE1k genotype is associated with altered suxamethonium metabolism, leading to prolonged apnea.
• This study highlights the importance of genetic screening for cholinesterase variants in patients with a history of adverse reactions to suxamethonium.
• Understanding familial cholinesterase genotypes is essential for personalized medicine and safe anesthetic practices.